CareDx, Inc. (CDNA) Stock Analysis

What CareDx (CDNA) Said on Its Q3 Earnings Call

Fri, October 30, 2026 at 12:14 AM UTC 4 min read

CareDx (CDNA) reported its Q3 earnings, highlighting a 15% year-over-year revenue growth driven by increased demand for its transplant diagnostics products. The company also announced a strategic partnership aimed at expanding its market reach, which could enhance future revenue streams. For investors, these developments signal strong operational performance and potential for continued growth in a competitive healthcare landscape.

Read full article →

CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus

Mon, October 26, 2026 at 12:58 PM UTC 2 min read

CareDx (CDNA) is set to report its Q3 earnings, with a particular emphasis on the growth of its transplant testing segment. This earnings report is significant for investors as it will provide insights into the company's performance and potential future growth, particularly in a market that increasingly values personalized medicine and transplant care solutions. Analysts will be closely watching the results to gauge the company's trajectory and market position.

Read full article →